# YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases

> **NCT07697937** · PHASE2 · RECRUITING · sponsor: **Tianjin First Central Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** YH-02

## Key facts

- **NCT ID:** NCT07697937
- **Lead sponsor:** Tianjin First Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-23
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697937, "YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*